Daclacee
Generic Name
Daclatasvir
Manufacturer
General Pharmaceuticals Ltd. (Bangladesh)
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| daclacee 60 mg tablet | ৳ 400.00 | ৳ 4,000.00 |
Description
Overview of the medicine
Daclacee (Daclatasvir) is an antiviral medication used in combination with other drugs, primarily Sofosbuvir, to treat chronic hepatitis C virus (HCV) infection of various genotypes.
Uses & Indications
Dosage
Adults
60 mg orally once daily, in combination with Sofosbuvir, for 12 or 24 weeks depending on genotype and cirrhosis status.
Elderly
No dose adjustment is required in elderly patients.
Renal_impairment
No dose adjustment is recommended for patients with mild to moderate renal impairment. Data for severe renal impairment or ESRD are limited, but generally considered safe.
How to Take
Daclacee (Daclatasvir) can be taken orally with or without food.
Mechanism of Action
Daclatasvir is a direct-acting antiviral agent that inhibits the hepatitis C virus (HCV) nonstructural protein 5A (NS5A), a phosphoprotein essential for HCV RNA replication and virion assembly.
Pharmacokinetics
Onset
Rapid onset of antiviral activity, observed within hours of the first dose.
Excretion
Mainly eliminated via feces (approximately 80%), with a minor renal contribution (approximately 6.6%).
Half life
Approximately 12-15 hours.
Absorption
Rapidly absorbed after oral administration, with peak plasma concentrations reached within 1-2 hours.
Metabolism
Primarily metabolized by cytochrome P450 3A4 (CYP3A4) enzyme.
Side Effects
Contraindications
- •Hypersensitivity to Daclatasvir or any component of the formulation.
- •Co-administration with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine, St. John's Wort) due to potential for significant reduction in Daclatasvir plasma levels, leading to loss of efficacy.
Drug Interactions
0
Strong CYP3A inducers (e.g., Rifampin, Phenytoin, Carbamazepine, St. John's Wort): Contraindicated. Significantly decreases Daclatasvir levels.
1
Strong CYP3A inhibitors (e.g., Ketoconazole, Clarithromycin, Ritonavir): May increase Daclatasvir levels; dose adjustment may be required.
2
Amiodarone: Co-administration with Sofosbuvir and Daclatasvir may lead to severe symptomatic bradycardia. Not recommended.
3
Statins (e.g., Rosuvastatin): Daclatasvir may increase exposure to certain statins. Monitor closely.
Storage
Store below 30°C (86°F), protect from light and moisture. Keep out of reach of children.
Overdose
No specific antidote for Daclatasvir overdose. Treatment should consist of general supportive measures, including monitoring of vital signs and observation of the patient's clinical status. Hemodialysis is unlikely to significantly remove Daclatasvir.
Pregnancy & Lactation
Pregnancy: Use not recommended unless potential benefits outweigh risks. Advise women of childbearing potential to use effective contraception during treatment. Lactation: Unknown if excreted in human milk. Decision to discontinue nursing or the drug should consider the importance of the drug to the mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Generally 24 to 36 months from the date of manufacture, specific to lot.
Availability
Available in pharmacies and hospitals
Approval Status
Approved by DGDA and international bodies
Patent Status
Generic available (due to voluntary licensing/compulsory licensing in some regions)
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
